# Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

> **NCT05803395** · — · UNKNOWN · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 954 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Indolent B-Cell Non-Hodgkin Lymphoma
- COVID-19

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05803395
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-12
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 954 (ESTIMATED)
- **Last updated:** 2023-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803395, "Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05803395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*